Precision medicine specialist Strata Oncology has partnered with the Sino-American drugmaker CBT Pharmaceuticals to drive patient enrollment in CBT’s ongoing Phase I/II trial of CBT-101. 11 December 2018
The first drug candidate from the research collaboration between Eisai, the Japanese pharma company, and University College London (UCL), is to enter Phase I trials in Alzheimer’s disease. 10 December 2018
Messenger RNA specialist Moderna Therapeutics raised more than $600 million in its IPO on Thursday, in line with analysts’ expectations, valuing the firm at $7.5 billion. 10 December 2018
Chugai Pharmaceutical has filed to broaden the Japanese label for the anti-PD-L1 monoclonal antibody Tecentriq (atezolizumab) for the first line treatment of extensive-stage small cell lung cancer (ES-SCLC). 7 December 2018
China’s WuXi Biologics has started the construction of new biologics drug substance manufacturing facility on the Industrial Development Authority's (IDA) greenfield site in Mullagharlin, Dundalk, County Louth, Ireland. 6 December 2018
Domain Therapeutics has announced a multi-target drug discovery collaboration and licensing agreement with privately-held German pharma major Boehringer Ingelheim on orphan G protein-coupled receptors (GPCRs) in the central nervous system (CNS) disease area. 5 December 2018
Japan-based Chugai Pharmaceutical, which is majority owned by Swiss pharma giant Roche, today announced that it has filed a patent infringement lawsuit at the Tokyo District Court against US drugmaker Alexion Pharmaceuticals. 5 December 2018
The Chinese business of German biopharma supplier Sartorius Stedim Biotech (SSB) has partnered with Beijing-based Immunochina Pharmaceuticals in a new collaboration. 5 December 2018
The local subsidiary of Japan’s Chugai has obtained approval from the Taiwan Food and Drug Administration (TFDA) for its bispecific monoclonal antibody Hemlibra (emicizumab-kxwh) for routine prophylaxis of bleeding episodes in patients with hemophilia A with factor VIII inhibitors by once weekly subcutaneous injection. 4 December 2018
Japanese major Astellas Pharma has launched its FLT3 (FMS-like tyrosine kinase 3) inhibitor Xospata (gilteritinib fumarate) in Japan for the indication of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations. 4 December 2018
The US regulator has accepted a Biologics License Application from Novartis for Zolgensma (onasemnogene abeparvovec-xxxx), an investigational gene replacement therapy for the treatment of spinal muscular atrophy Type 1. 3 December 2018
Japan’s Daiichi Sankyo has announced it is restructuring its vaccines business, Kitasato Daiichi Sankyo Vaccine, merging it into the parent company. 30 November 2018
Spark Therapeutics, a commercial gene therapy company, is moving to the Schuylkill Yards development in University City, Philadelphia. 29 November 2018
Massachusetts, USA-based Moderna Therapeutics has set terms for its upcoming initial public offering (IPO), with plans to offer 21.7 million shares at between $22 and $24 each on the Nasdaq market under the ticker symbol MRNA. 29 November 2018
US biotech Q BioMed has entered into agreement to acquire the metastatic skeletal cancer palliation drug, Metastron (strontium-89 chloride), from GE Healthcare. 28 November 2018
Belgium’s ASIT Biotech today announced that it has installed and qualified in a clean room the equipment to produce, in compliance with Good Manufacturing Practices (GMP) requirements, the active pharmaceutical ingredient (API) for the Phase I/II studies in house dust mite and peanut allergies treatment. 26 November 2018
The European Investment Bank (EIB) is lending 24 million euros ($27.3 million) to Austrian F2G Biotech, a research-intensive company, focusing on the discovery and development of novel drugs to treat life threatening fungal diseases. 22 November 2018
Oxford, UK-based OMass Therapeutics has raised £14 million ($18 million) in a series A financing round, led by Syncona, alongside Oxford Sciences Innovation (OSI). 21 November 2018
Genevant Sciences has appointed Bo Rode Hansen, the former global head of RNA therapeutics at Roche, as president and chief executive officer. 20 November 2018
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024